Can Generic Pharmas Use PGx Tools to Create Niche Products and Rouse Slumping Margins? | GenomeWeb

Generic pharmaceutical companies hoping to eke out some extra revenue in an increasingly crowded market may soon be turning to pharmacogenomics technologies, according to several industry insiders.

In getting involved in this new area, generic drug makers will most likely seek to identify biomarkers and develop molecular diagnostics that would help them sell off-patent compounds at a premium. Marketing these so-called niche generics to physicians, generic pharmas will claim their version is safer and more efficacious in a certain population of patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.